Diabetic Macular Edema Market Report and Forecast 2025-2034
Description
The diabetic macular edema market size was valued at USD 6.70 Billion in 2024, driven by the increasing incidence of diabetes cases within the 8 major markets. The market size is anticipated to grow at a CAGR of 5.10% during the forecast period of 2025-2034 to achieve a value of USD 11.02 Billion by 2034.
Diabetic Macular Edema Market Overview
Diabetic retinopathy occurs in people with diabetes where the tiny blood vessels located at the back inner wall of the eye, known as the retina, get damaged or blocked by too much blood sugar. This can result in the formation of microaneurysms, which are tiny bulges in the blood vessels that leak fluid into the retina. The swollen fluid can cause vision problems or blindness in a part of the retina known as the macula, which is referred to as diabetic macular edema.
The market is driven by the rising prevalence of diabetes and diabetic macular edema. The prevalence rate of diabetic macular edema (DME) in type 2 diabetes patients is recorded to be higher than in type 1 diabetes patients. It is estimated that neovascular age-related macular degeneration (AMD) affects more than 200 million people worldwide. The increase in the number of research and development activities providing beneficial opportunities for treatment are driving the diabetic macular edema market growth. The rising approvals and launches of new drugs, along with rising investment in the development of advanced technologies is also expected to contribute to the market growth during the forecast period.
Technological Advancements to Develop Effective Solutions
The market growth is expected to be driven by several factors such as increased advancements in diagnostics technology and therapeutics for diabetic macular edema. For instance, in July 2023 researchers at the University of Waterloo’s School of Pharmacy developed a novel synthetic protein to treat macular degeneration and other incurable eye diseases that lead to blindness in millions of people. It is the first drug of its kind and is currently in human trials. Continuous efforts like these, focused at developing a cure for untreatable conditions are likely to increase the diabetic macular edema market share in the forecast period.
FDA Approvals to Aid the Market Growth
The market growth is propelled by rising FDA approvals to potent and cost-effective solutions to the patients. For instance, in August 2023, the United States FDA approved Regeneron’s EYLEA HD (aflibercept) Injection 8 mg for treating diabetic macular edema and other eye conditions. The approval was based on the results of 48-week PULSAR and PHOTON trials, wherein the potential candidate helped in significant vision gains in patients. This FDA approval will contribute to the widespread distribution and consumption of the pharmaceutical resulting in increased diabetic macular edema market value in the forecast period.
Diabetic Macular Edema Market Segmentations
Diabetic Macular Edema Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type Germany
France
Italy
Spain
United Kingdom
Geographically, the United States is expected to lead throughout the forecast period, owing to the presence of a robust healthcare system and major market players. The continuous research activities in the region also contribute to the market growth. There has been significant emphasis on leveraging gene therapy to allow access to improved solutions. In November 2023, scientists deployed gene therapy ABBV-RGX-314 to allow controlled release of dexamethasone in patients with diabetic macular edema and retinal vein occlusion. Developed by collaborative efforts of RegenXBio and AbbVie, ABBV-RGX-314 is a monoclonal antibody fragment, administered through an injection. When tested in a cohort of 100 patients with DME, it reduced vision threatening events by 89% and prevented disease progression as well. Hence, it can be used as a potential treatment in the future.
Europe, with its robust healthcare infrastructure and significant portion of geriatric population has high diabetic macular edema market demand. Consequently, the existence of prominent academic and research institutions aids market size, with continuous developments and activities to develop effective solutions for the patients in the region.
Diabetic Macular Edema Market: Competitor Landscape
In May 2023, Oculis, a global pharmaceutical company prioritising eye care, revealed that their latest topical eye drop OCS-01, displayed positive results from stage 1 of phase 3 DIAMOND trial . The treatment provides an edge over current treatment alternatives of the disease, which mostly involve ocular implants or injections. It utilises Oculis' Optireach technology to deliver the effective medication to the retina. The rising prevalence for minimally invasive treatment alternatives has led to the development of relevant initiatives by industry leaders.
The key features of the diabetic macular edema market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Diabetic Macular Edema Market Overview
Diabetic retinopathy occurs in people with diabetes where the tiny blood vessels located at the back inner wall of the eye, known as the retina, get damaged or blocked by too much blood sugar. This can result in the formation of microaneurysms, which are tiny bulges in the blood vessels that leak fluid into the retina. The swollen fluid can cause vision problems or blindness in a part of the retina known as the macula, which is referred to as diabetic macular edema.
The market is driven by the rising prevalence of diabetes and diabetic macular edema. The prevalence rate of diabetic macular edema (DME) in type 2 diabetes patients is recorded to be higher than in type 1 diabetes patients. It is estimated that neovascular age-related macular degeneration (AMD) affects more than 200 million people worldwide. The increase in the number of research and development activities providing beneficial opportunities for treatment are driving the diabetic macular edema market growth. The rising approvals and launches of new drugs, along with rising investment in the development of advanced technologies is also expected to contribute to the market growth during the forecast period.
Technological Advancements to Develop Effective Solutions
The market growth is expected to be driven by several factors such as increased advancements in diagnostics technology and therapeutics for diabetic macular edema. For instance, in July 2023 researchers at the University of Waterloo’s School of Pharmacy developed a novel synthetic protein to treat macular degeneration and other incurable eye diseases that lead to blindness in millions of people. It is the first drug of its kind and is currently in human trials. Continuous efforts like these, focused at developing a cure for untreatable conditions are likely to increase the diabetic macular edema market share in the forecast period.
FDA Approvals to Aid the Market Growth
The market growth is propelled by rising FDA approvals to potent and cost-effective solutions to the patients. For instance, in August 2023, the United States FDA approved Regeneron’s EYLEA HD (aflibercept) Injection 8 mg for treating diabetic macular edema and other eye conditions. The approval was based on the results of 48-week PULSAR and PHOTON trials, wherein the potential candidate helped in significant vision gains in patients. This FDA approval will contribute to the widespread distribution and consumption of the pharmaceutical resulting in increased diabetic macular edema market value in the forecast period.
Diabetic Macular Edema Market Segmentations
Diabetic Macular Edema Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- Focal Diabetic Macular Edema (DME)
- Diffuse Diabetic Macular Edema (DME)
- Oral Iron Therapy
- Parenteral Iron Therapy
- Red Blood Cell Transfusion
- Hospitals Fluorescein Angiography
- Fundus Imaging
- Optical Coherence Tomography (OCT)
- Others
- Intravitreal Injections
- Intravitreal Implants
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- Hospitals
- Clinics
- Home Healthcare
- Others
- United States
- EU-4 and the United Kingdom
- Japan
- India
Geographically, the United States is expected to lead throughout the forecast period, owing to the presence of a robust healthcare system and major market players. The continuous research activities in the region also contribute to the market growth. There has been significant emphasis on leveraging gene therapy to allow access to improved solutions. In November 2023, scientists deployed gene therapy ABBV-RGX-314 to allow controlled release of dexamethasone in patients with diabetic macular edema and retinal vein occlusion. Developed by collaborative efforts of RegenXBio and AbbVie, ABBV-RGX-314 is a monoclonal antibody fragment, administered through an injection. When tested in a cohort of 100 patients with DME, it reduced vision threatening events by 89% and prevented disease progression as well. Hence, it can be used as a potential treatment in the future.
Europe, with its robust healthcare infrastructure and significant portion of geriatric population has high diabetic macular edema market demand. Consequently, the existence of prominent academic and research institutions aids market size, with continuous developments and activities to develop effective solutions for the patients in the region.
Diabetic Macular Edema Market: Competitor Landscape
In May 2023, Oculis, a global pharmaceutical company prioritising eye care, revealed that their latest topical eye drop OCS-01, displayed positive results from stage 1 of phase 3 DIAMOND trial . The treatment provides an edge over current treatment alternatives of the disease, which mostly involve ocular implants or injections. It utilises Oculis' Optireach technology to deliver the effective medication to the retina. The rising prevalence for minimally invasive treatment alternatives has led to the development of relevant initiatives by industry leaders.
The key features of the diabetic macular edema market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- LEO Pharma
- Amneal Pharmaceuticals
- AstraZeneca
- Johnson & Johnson Private Limited
- Bausch Health Companies Inc.
- Eli Lilly and Company
- AbbVie Inc.
- Abbott
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Diabetic Macular Edema Market Overview – 8 Major Markets
- 3.1 Diabetic Macular Edema Market Historical Value (2018-2024)
- 3.2 Diabetic Macular Edema Market Forecast Value (2025-2034)
- 4 Diabetic Macular Edema Overview
- 4.1 Guidelines and Stages
- 4.2 Pathophysiology
- 4.3 Screening and Diagnosis
- 4.4 Treatment Pathway
- 5 Patient Profile
- 5.1 Patient Profile Overview
- 5.2 Patient Psychology and Emotional Impact Factors
- 5.3 Risk Assessment and Treatment Success Rate
- 6 Diabetic Macular Edema Epidemiology Scenario and Forecast – 8 Major Markets
- 6.1 8MM Epidemiology Scenario Overview (2018-2034)
- 6.2 United States Diabetic Macular Edema Epidemiology Scenario and Forecast (2018-2034)
- 6.3 EU-4 and United Kingdom Diabetic Macular Edema Epidemiology Scenario and Forecast (2018-2034)
- 6.3.1 Germany Diabetic Macular Edema Epidemiology Scenario and Forecast (2018-2034)
- 6.3.2 France Diabetic Macular Edema Epidemiology Scenario and Forecast (2018-2034)
- 6.3.3 Italy Diabetic Macular Edema Epidemiology Scenario and Forecast (2018-2034)
- 6.3.4 Spain Diabetic Macular Edema Epidemiology Scenario and Forecast (2018-2034)
- 6.3.5 United Kingdom Diabetic Macular Edema Epidemiology Scenario and Forecast (2018-2034)
- 6.4 Japan Diabetic Macular Edema Epidemiology Scenario and Forecast (2018-2034)
- 6.5 India Diabetic Macular Edema Epidemiology Scenario and Forecast (2018-2034)
- 7 Diabetic Macular Edema Market Landscape – 8 Major Markets
- 7.1 Diabetic Macular Edema: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Diabetic Macular Edema: Product Landscape
- 7.2.1 Analysis by Treatment
- 7.2.2 Analysis by Product Type
- 8 Diabetic Macular Edema Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Diabetic Macular Edema Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.2.1 Strengths
- 10.2.2 Weaknesses
- 10.2.3 Opportunities
- 10.2.4 Threats
- 10.3 Porter’s Five Forces Model
- 10.3.1 Bargaining Power of Suppliers
- 10.3.2 Bargaining Power of Buyers
- 10.3.3 Threat of New Entrants
- 10.3.4 Threat of Substitutes
- 10.3.5 Degree of Rivalry
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Diabetic Macular Edema Market Segmentation (218-2034) - 8 Major Markets
- 11.1 Diabetic Macular Edema Market (2018-2034) by Disease Type
- 11.1.1 Market Overview
- 11.1.2 Focal Diabetic Macular Edema (DME)
- 11.1.3 Diffuse Diabetic Macular Edema (DME)
- 11.2 Diabetic Macular Edema Market (2018-2034) by Treatment Type
- 11.2.1 Market Overview
- 11.2.2 Oral Iron Therapy
- 11.2.3 Parenteral Iron Therapy
- 11.2.4 Red Blood Cell Transfusion
- 11.3 Diabetic Macular Edema Market (2018-2034) by Diagnosis
- 11.3.1 Market Overview
- 11.3.2 Hospitals Fluorescein Angiography
- 11.3.3 Fundus Imaging
- 11.3.4 Optical Coherence Tomography (OCT)
- 11.3.5 Others
- 11.4 Diabetic Macular Edema Market (2018-2034) by Route of Administration
- 11.4.1 Market Overview
- 11.4.2 Intravitreal Injections
- 11.4.3 Intravitreal Implants
- 11.5 Diabetic Macular Edema Market (2018-2034) by Distribution Channel
- 11.5.1 Market Overview
- 11.5.2 Hospital Pharmacy
- 11.5.3 Retail Pharmacy
- 11.5.4 Online Pharmacy
- 11.5.5 Others
- 11.6 Diabetic Macular Edema Market (2018-2034) by End User
- 11.6.1 Market Overview
- 11.6.2 Hospitals
- 11.6.3 Clinics
- 11.6.4 Home Healthcare
- 11.6.5 Others
- 11.7 Diabetic Macular Edema Market (2018-2034) by Region
- 11.7.1 Market Overview
- 11.7.2 United States
- 11.7.3 EU-4 and the United Kingdom
- 11.7.3.1 Germany
- 11.7.3.2 France
- 11.7.3.3 Italy
- 11.7.3.4 Spain
- 11.7.3.5 United Kingdom
- 11.7.4 Japan
- 11.7.5 India
- 12 United States Diabetic Macular Edema Market (218-2034)
- 12.1 United States Diabetic Macular Edema Market Historical Value (2018-2024)
- 12.2 United States Diabetic Macular Edema Market Forecast Value (2025-2034)
- 12.3 United States Diabetic Macular Edema Market (2018-2034) by Disease Type
- 12.3.1 Market Overview
- 12.3.2 Focal Diabetic Macular Edema (DME)
- 12.3.3 Diffuse Diabetic Macular Edema (DME)
- 12.4 United States Diabetic Macular Edema Market (2018-2034) by Treatment Type
- 12.4.1 Market Overview
- 12.4.2 Oral Iron Therapy
- 12.4.3 Parenteral Iron Therapy
- 12.4.4 Red Blood Cell Transfusion
- 13 EU-4 and United Kingdom Diabetic Macular Edema Market (218-2034)
- 13.1 EU-4 and United Kingdom Diabetic Macular Edema Market Historical Value (2018-2024)
- 13.2 EU-4 and United Kingdom Diabetic Macular Edema Market Forecast Value (2025-2034)
- 13.3 EU-4 and United Kingdom Diabetic Macular Edema Market Overview
- 13.4 EU-4 and United Kingdom Diabetic Macular Edema Market (2018-2034) by Disease Type
- 13.4.1 Market Overview
- 13.4.2 Focal Diabetic Macular Edema (DME)
- 13.4.3 Diffuse Diabetic Macular Edema (DME)
- 13.5 EU-4 and United Kingdom Diabetic Macular Edema Market (2018-2034) by Treatment Type
- 13.5.1 Market Overview
- 13.5.2 Oral Iron Therapy
- 13.5.3 Parenteral Iron Therapy
- 13.5.4 Red Blood Cell Transfusion
- 14 Japan Diabetic Macular Edema Market
- 14.1 Japan Diabetic Macular Edema Market Historical Value (2018-2024)
- 14.2 Japan Diabetic Macular Edema Market Forecast Value (2025-2034)
- 14.3 Japan Diabetic Macular Edema Market (2018-2034) by Disease Type
- 14.3.1 Market Overview
- 14.3.2 Focal Diabetic Macular Edema (DME)
- 14.3.3 Diffuse Diabetic Macular Edema (DME)
- 14.4 Japan Diabetic Macular Edema Market (2018-2034) by Treatment Type
- 14.4.1 Market Overview
- 14.4.2 Oral Iron Therapy
- 14.4.3 Parenteral Iron Therapy
- 14.4.4 Red Blood Cell Transfusion
- 15 India Diabetic Macular Edema Market
- 15.1 India Diabetic Macular Edema Market (2018-2034) Historical Value (2018-2024)
- 15.2 India Diabetic Macular Edema Market (2018-2034) Forecast Value (2025-2034)
- 15.3 India Diabetic Macular Edema Market (2018-2034) by Disease Type
- 15.3.1 Market Overview
- 15.3.2 Focal Diabetic Macular Edema (DME)
- 15.3.3 Diffuse Diabetic Macular Edema (DME)
- 15.4 India Diabetic Macular Edema Market (2018-2034) by Treatment Type
- 15.4.1 Market Overview
- 15.4.2 Oral Iron Therapy
- 15.4.3 Parenteral Iron Therapy
- 15.4.4 Red Blood Cell Transfusion
- 16 Regulatory Framework
- 16.1 Regulatory Overview
- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 Japan PMDA
- 16.1.4 Others
- 17 Patent Analysis
- 17.1 Analysis by Type of Patent
- 17.2 Analysis by Publication Year
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Patent Age
- 17.5 Analysis by CPC Analysis
- 17.6 Analysis by Patent Valuation
- 17.7 Analysis by Key Players
- 18 Grants Analysis
- 18.1 Analysis by Year
- 18.2 Analysis by Amount Awarded
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Grant Application
- 18.5 Analysis by Funding Institute
- 18.6 Analysis by NIH Departments
- 18.7 Analysis by Recipient Organization
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Funding and Investment Analysis
- 20.1 Analysis by Funding Instances
- 20.2 Analysis by Type of Funding
- 20.3 Analysis by Funding Amount
- 20.4 Analysis by Leading Players
- 20.5 Analysis by Leading Investors
- 20.6 Analysis by Geography
- 21 Partnership and Collaborations Analysis
- 21.1 Analysis by Partnership Instances
- 21.2 Analysis by Type of Partnership
- 21.3 Analysis by Leading Players
- 21.4 Analysis by Geography
- 22 Supplier Landscape
- 22.1 LEO Pharma
- 22.1.1 Financial Analysis
- 22.1.2 Product Portfolio
- 22.1.3 Demographic Reach and Achievements
- 22.1.4 Mergers and Acquisitions
- 22.1.5 Certifications
- 22.2 Amneal Pharmaceuticals
- 22.2.1 Financial Analysis
- 22.2.2 Product Portfolio
- 22.2.3 Demographic Reach and Achievements
- 22.2.4 Mergers and Acquisitions
- 22.2.5 Certifications
- 22.3 AstraZeneca
- 22.3.1 Financial Analysis
- 22.3.2 Product Portfolio
- 22.3.3 Demographic Reach and Achievements
- 22.3.4 Mergers and Acquisitions
- 22.3.5 Certifications
- 22.4 Johnson & Johnson Private Limited
- 22.4.1 Financial Analysis
- 22.4.2 Product Portfolio
- 22.4.3 Demographic Reach and Achievements
- 22.4.4 Mergers and Acquisitions
- 22.4.5 Certifications
- 22.5 Bausch Health Companies Inc.
- 22.5.1 Financial Analysis
- 22.5.2 Product Portfolio
- 22.5.3 Demographic Reach and Achievements
- 22.5.4 Mergers and Acquisitions
- 22.5.5 Certifications
- 22.6 Eli Lilly and Company
- 22.6.1 Financial Analysis
- 22.6.2 Product Portfolio
- 22.6.3 Demographic Reach and Achievements
- 22.6.4 Mergers and Acquisitions
- 22.6.5 Certifications
- 22.7 AbbVie Inc.
- 22.7.1 Financial Analysis
- 22.7.2 Product Portfolio
- 22.7.3 Demographic Reach and Achievements
- 22.7.4 Mergers and Acquisitions
- 22.7.5 Certifications
- 22.8 Abbott
- 22.8.1 Financial Analysis
- 22.8.2 Product Portfolio
- 22.8.3 Demographic Reach and Achievements
- 22.8.4 Mergers and Acquisitions
- 22.8.5 Certifications
- 22.9 F. Hoffmann-La Roche Ltd.
- 22.9.1 Financial Analysis
- 22.9.2 Product Portfolio
- 22.9.3 Demographic Reach and Achievements
- 22.9.4 Mergers and Acquisitions
- 22.9.5 Certifications
- 22.10 Mylan N.V.
- 22.10.1 Financial Analysis
- 22.10.2 Product Portfolio
- 22.10.3 Demographic Reach and Achievements
- 22.10.4 Mergers and Acquisitions
- 22.10.5 Certifications
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
